androgen receptor pathway inhibitors (ARPIs)
Cancer
Hormone-sensitive prostate cancer
multimodal therapy survival outcomes
personalized treatment intensification
PSMA PET imaging
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
, /PRNewswire/ — GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik’s team at Asan Medical Center has been published…
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals’ radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration , /PRNewswire/ — SK Biopharmaceuticals, CO., Ltd., a biotech company…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies…
Elanco executive appointed as Neurizon’s Board Observer
, /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased…
Elanco executive appointed as Neurizon’s Board Observer
, /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased…
Beyond Air® Announces Transition of Chief Financial Officer
Launched search for permanent successor GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and…
Tilray Brands Announces Implementation of Previously Approved 1-for-10 Reverse Stock Split
Common Stock Expected to Begin Trading on a Split-Adjusted Basis on December 2, 2025 NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray Brands”, “Tilray” or “the…
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic…
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic…
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants BRISBANE, Calif., Nov. 26, 2025 (GLOBE…